Characterizing the 'feel-good experience' in multiple sclerosis patients treated with natalizumab or other therapies

被引：6

作者：

Foley, John ^{[1
]}

Berkovich, Regina ^{[2
]}

Gudesblatt, Mark ^{[3
]}

Luce, Elizabeth ^{[4
]}

Schneider, Beth ^{[4
]}

de Moor, Carl ^{[5
]}

Liao, Shirley ^{[5
]}

Lee, Lily ^{[5
]}

Bodhinathan, Karthik ^{[5
]}

Avila, Robin ^{[5
]}

机构：

[1] Rocky Mt MS Clin, Salt Lake City, UT 80031 USA

[2] Los Angeles Cty & USC Med Ctr, Neurol Program, Los Angeles, CA 90033 USA

[3] South Shore Neurol Associates, Patchogue, NY 11772 USA

[4] MyHealthTeam, San Francisco, CA 94104 USA

[5] Biogen, Cambridge, MA 02142 USA

来源：

NEURODEGENERATIVE DISEASE MANAGEMENT | 2023年 / 13卷 / 01期

关键词：

disease-modifying therapy; feel-good experience; multiple sclerosis; natalizumab; patient management; patient-reported outcomes; quality-of-life; real-world evidence; QUALITY-OF-LIFE;

D O I：

10.2217/nmt-2022-0003

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Aim: Patients with relapsing-remitting multiple sclerosis (RRMS) treated with natalizumab have anecdotally reported a 'feel-good experience' (FGE). The authors characterized the FGE using survey data from patients with RRMS treated with natalizumab or other disease-modifying therapies (other-DMT). Methods: Questionnaire data from RRMS patients who use MyMSTeam, an online patient social network, were analyzed. Results: The survey included 347 patients (95 natalizumab; 252 other-DMT). More natalizumab than other-DMT patients self-reported having an FGE (62.1 vs 44.8%; p = 0.001) as well as other physical, emotional and cognitive benefits. Conclusion: This study demonstrates that physical, emotional and cognitive benefits were more commonly reported by patients treated with natalizumab than those treated with other disease-modifying therapies and helps characterize patient-reported factors associated with the FGE.

引用

收藏

页码：23 / 34

页数：12

相关论文

共 22 条

[1] Health-related quality of life as an independent predictor of long-term disability for patients with relapsingremitting multiple sclerosis [J].

Baumstarck, K. ;

Pelletier, J. ;

Butzkueven, H. ;

Fernandez, O. ;

Flachenecker, P. ;

Idiman, E. ;

Stecchi, S. ;

Boucekine, M. ;

Auquier, P. .

EUROPEAN JOURNAL OF NEUROLOGY, 2013, 20 (06) :907-E79

[2]

Berkovich, 2018, CMSC

[3] Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy [J].

Bringeland, Gerd Haga ;

Blaser, Nello ;

Myhr, Kjell-Morten ;

Vedeler, Christian Alexander ;

Gavasso, Sonia .

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2020, 7 (03)

[4] Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP) [J].

Butzkueven, Helmut ;

Kappos, Ludwig ;

Wiendl, Heinz ;

Trojano, Maria ;

Spelman, Tim ;

Chang, Ih ;

Kasliwal, Rachna ;

Jaitly, Seema ;

Campbell, Nolan ;

Ho, Pei-Ran ;

Licata, Stephanie .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2020, 91 (06) :660-668

[5] Long- term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis [J].

Foley, John F. ;

Nair, Kavita V. ;

Vollmer, Timothy ;

Stephenson, Judith J. ;

Niecko, Timothy ;

Agarwal, Sonalee S. ;

Watson, Crystal .

PATIENT PREFERENCE AND ADHERENCE, 2017, 11 :1035-1048

[6] Predictors for Employment Status in People With Multiple Sclerosis: A 10-Year Longitudinal Observational Study [J].

Forslin, Mia ;

Fink, Katharina ;

Hammar, Ulf ;

von Koch, Lena ;

Johansson, Sverker .

ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION, 2018, 99 (08) :1483-1490

[7] Evaluating Treatment Patterns, Relapses, Healthcare Resource Utilization, and Costs Associated with Disease-Modifying Treatments for Multiple Sclerosis in DMT-Naive Patients [J].

Freeman, Leorah ;

Kee, Arianna ;

Tian, Marc ;

Mehta, Rina .

CLINICOECONOMICS AND OUTCOMES RESEARCH, 2021, 13 :65-75

[8] The association between cognitive impairment and quality of life in patients with early multiple sclerosis [J].

Glanz, Bonnie I. ;

Healy, Brian C. ;

Rintell, David J. ;

Jaffin, Sharon K. ;

Bakshi, Rohit ;

Weiner, Howard L. .

JOURNAL OF THE NEUROLOGICAL SCIENCES, 2010, 290 (1-2) :75-79

[9] Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis [J].

Gudesblatt, Mark ;

Wissemann, Karl ;

Zarif, Myassar ;

Bumstead, Barbara ;

Fafard, Lori ;

Wilken, Jeffrey ;

Blitz, Karen ;

Buhse, Marijean ;

Santra, Sourav ;

Hotermans, Christophe ;

Lee, Lily .

CNS DRUGS, 2018, 32 (12) :1173-1181

[10] Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: Results from MS PATHS [J].

Hersh, Carrie M. ;

Kieseier, Bernd ;

de Moor, Carl ;

Miller, Deborah M. ;

Campagnolo, Denise ;

Williams, James R. ;

Fitzgerald, Kathryn C. ;

Xiong, Kuangnan ;

McGinley, Marisa P. ;

Hyland, Megan ;

Rudick, Richard A. ;

Ziemssen, Tjalf ;

Koulinska, Irene .

MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2021, 7 (02)